

Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas

Objectives

- Review the role of Bruton Tyrosine Kinase (BTK) Inhibitors in B-Cell lymphomas
- Discuss the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-Cell lymphomas
- Compare and contrast the safety profiles of the BTK inhibitors
 Review novel regimens and ongoing clinical trials that may impact the treatment landscape